Brief: Vertex announces broad reimbursement agreement With NHS England for Alyftrek for the treatment of cystic fibrosis
15/07/2025 24:03
July 15 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES BROAD REIMBURSEMENT AGREEMENT WITH NHS ENGLAND FOR ALYFTREK® (DEUTIVACAFTOR/TEZACAFTOR/VANZACAFTOR) AN INNOVATIVE ONCE-DAILY CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS Source text: ID:nBwbZXs74a Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31